Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study - Report - MDSpire

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

  • By

  • Andrew Blauvelt

  • H. Chih-Ho Hong

  • Norito Katoh

  • Richard G. Langley

  • Vivian Laquer

  • Aleksandra Lesiak

  • Ketty Peris

  • Julien Seneschal

  • Juan-Francisco Silvestre

  • Richard B. Warren

  • Andreas Wollenberg

  • Matthew Zirwas

  • Niels Højsager Bennike

  • Farzaneh Safavimanesh

  • Ann-Marie Tindberg

  • Kristian Reich

  • February 5, 2026

  • 0 min

Share

Clinical Report: Extended Safety and Effectiveness of Tralokinumab in AD

Overview

Tralokinumab demonstrated long-term safety and efficacy in individuals with moderate-to-severe atopic dermatitis (AD) over a 6-year period. The treatment was well tolerated, with no new safety signals identified, supporting its favorable benefit-to-risk profile.

Background

Atopic dermatitis is a chronic inflammatory skin disease that significantly affects patients' quality of life. There is a clinical need for effective treatments that provide stable disease control over extended periods. Tralokinumab, a monoclonal antibody targeting interleukin-13, has been approved for moderate-to-severe AD, making its long-term safety and efficacy critical for patient management.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • Tralokinumab was well tolerated in patients treated for up to 6 years.
  • No new safety signals were identified during the long-term treatment period.
  • Long-term treatment maintained disease control in patients aged ≥ 12 years.
  • Patients showed sustained efficacy with improvements in key clinical measures.
  • The findings support the favorable benefit-to-risk profile of tralokinumab for chronic use.

Clinical Implications

Healthcare providers can consider tralokinumab as a long-term treatment option for patients with moderate-to-severe atopic dermatitis, given its established safety and efficacy profile. Continuous monitoring for treatment-emergent adverse events remains essential.

Conclusion

The ECZTEND study provides robust evidence supporting the long-term use of tralokinumab in managing moderate-to-severe atopic dermatitis, reinforcing its role in clinical practice.

References

  1. Clinical Rheumatology, 2019 -- Long-term Efficacy and Safety of Tocilizumab in Rheumatoid Arthritis Patients with Insufficient Response to csDMARDs and/or TNF Inhibitors: An Open-Label Study Reflecting Clinical Practice
  2. Clinical Rheumatology, 2018 -- Extended Open-Label Study on the Safety of Tocilizumab in Polish and Russian Patients with Polyarticular Juvenile Idiopathic Arthritis Following the CHERISH Trial Completion
  3. Clinical Rheumatology, 2024 -- Long-term Use of Subcutaneous Tocilizumab Alone or with Synthetic DMARDs in Rheumatoid Arthritis Patients in Greece: Findings from the EMBRACE Multicenter Observational Study
  4. Drug Safety, 2019 -- Safety Profile of Ustekinumab in Patients with Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: A Comprehensive Review of Phase II/III Clinical Trials
  5. European Guideline (EuroGuiDerm) on atopic eczema: Living update - PubMed
  6. Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND - PMC
  7. Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis - PubMed
  8. European Guideline (EuroGuiDerm) on atopic eczema: Living update - PubMed
  9. Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND - PMC
  10. Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis - PubMed

Original Source(s)

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

  • by Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, Andreas Wollenberg, Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimanesh, Ann-Marie Tindberg, Kristian Reich

  • February 5, 2026

Related Content

Atopic Dermatitis Treatment Targets Defined

Consensus definitions for disease control in atopic dermatitis aim to standardize clinical trial end points and support treat-to-target strategies.

Dupilumab and Lymphoma Risk in AD?

Dupilumab is safe from a lymphoma-risk perspective in atopic dermatitis and other type 2 inflammatory diseases, based on real-world data.

Ivermectin vs Permethrin for Scabies

Investigators evaluate household-level cure rates in dermoscopy-confirmed cases at day 28.